CoChat
Sign Up
Cited by 124Pain Management and Opioid UseOpioid Use Disorder TreatmentAnesthesia and Pain Management

Pharmacology of opioids in the treatment of chronic pain syndromes

Open access
Vallejo, Ricardo·2011·Pain Physician
DOI 10.36076/ppj.2011/14/e343
Open this paper in CoChat — free account

Abstract

The perpetual pursuit of pain elimination has been constant throughout human history and pervades human cultures. In some ways it is as old as medicine itself. Cultures throughout history have practiced the art of pain management through remedies such as oral ingestion of herbs or techniques believed to have special properties. In fact, even Hippocrates wrote about the practice of trepanation, the cutting of holes in the body to release pain. Current therapies for management of pain include the pervasive utilization of opioids, which have an extensive history, spanning centuries. There is general agreement about the appropriateness of opioids for the treatment of acute and cancer pain, but the long-term use of these drugs for treatment of chronic non-malignant pain remains controversial. The pros and cons regarding these issues are beyond the scope of this review. Instead, the purpose of this review will be directed towards the pharmacology of commonly prescribed opioids in the treatment of various chronic pain syndromes. Opium, derived from the Greek word for “juice,” is extracted from the latex sap of the opium poppy (Papaverum somniferum). The juice of the poppy is the source of some 20 different alkaloids of opium. These alkaloids of opioids can be divided into 2 chemical classes: phenanthrenes (morphine, codeine, and thebaine) and benzylisoquinolines (agents that do not interact with opioid receptors). Key words: Opioid metabolism, opioid interactions, morphine, codeine, hydrocodone, oxycodone, hydromorphone, methadone, intractable pain, endorphins, enkephalins, dynorphins, narcotics, pharmacology, propoxyphene, fentanyl, oxymorphone, tramadol

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.36076/ppj.2011/14/e343

Cites

161 of 161 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

3 of the 164 references couldn’t be matched to a known paper.

Research works printed but not linked: 35

  1. [5]5. Barkin RL. Incorporation of science and clinical medicine in the process of pa- tient-specific and patient-centered, pa- tient focused prescribing and personal- ize patient care. Pain Med Network 2008; 23:4-9.
  2. [6]6. Foley KM. Opioids. Neurol Clin 1993; 11:503-522.
  3. [9]9. Leone P, Pocock D, Wise RA. Morphine dopamine interaction: Ventral tegmen- tal morphine increases nucleus accum- bens dopamine release. Pharmacol Bio- chem Beh 1991; 39:469-472.
  4. [10]10. Matthews RT, German DC. Electro- www.painphysicianjournal.com inhibitory action of opioids on synaptic transmission in the rat periaqueductal grey in vitro. J Physiol 1997; 498:463-467.
  5. [13]13. Jhamandas KH. Opioid-neurotransmit- ter interactions: Significance in anal- gesia, tolerance and dependence. Prog Neuro-Psychopharmacol Biol Psychiatr 1984; 8:565-570.
  6. [18]18. Thompson JW. Opioid peptides. Br Med J 1984; 288:259-261.
  7. [20]20. Simon EJ, Hiller JM. The opiate recep- tors. Ann Rev Pharmacol Toxicol 1978; 18:371-394.
  8. [21]21. McDonald J, Lambert DC. Opioid recep- tors. CEACCP 2005; 5:22-25.
  9. [22]22. Coda BA. Clinical Anesthesia. 6th Ed. Lippincott Williams & Wilkins, Philadel- phia, 2009, pp 464-497.
  10. [26]26. Kupers RC, Konings H, Adriaensen H, Gybels JM. Morphine differentially af- fects sensory and affective pain ratings in neurogenic and diopathic forms of pain. Pain 1991; 47:5-12.
  11. [28]28. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11:S133-153.
  12. [30]30. van Dorp EL, Romberg R, Sarton E, Bo- vill JG, Dahan A. Morphine-6-glucuro- nide: Morphine's successor for postop- erative pain relief? Anesth Analg 2006; 102:1789-1797.
  13. [31]31. Jenkins AJ. Pharmacokinetics of specif- ic drugs. In Karch SB (ed). Pharmacoki- netics and Pharmacodynamics of Abused Drugs. CRC Press, Boca Raton, 2008, pp 25-64.
  14. [42]42. Anton B, Fein J, To T, Li X, Silberstein L, Evans CJ. Immunohistochemical local- ization of ORL-1 in the central nervous system of the rat. J Comp Neurol 1996; 368:229-251.
  15. [49]49. Vaughan CW, Christie MJ. Presynaptic 1984; 56:821-827.
  16. [59]59. Wright AW, Mather LE, Smith MT. Hy- dromophone-3-glucuronide: A more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69: 409-420.
  17. [61]61. Thwaites D, McCann S, Broderick P. Hy- dromophone neuroexcitation. J Palliat Med 2004 ;7:545-550.
  18. [63]63. Smith HS. Opioid metabolism. Mayo Clin Proc 2009; 84:613-624.
  19. [72]72. Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl in the man- agement of pain. Drugs 2010; 70:57-72.
  20. [93]93. Latta KS, Ginsberg B, Barkin RL. Meper- idine: A critical review. Am J of Ther 2002; 9:53-58.
  21. [95]95. Ikeda T, Kurz A, Sessler DI, Go J, Kurz M, Belani K, Larson M, Bjorksten AR, Dechert M, Christensen R. The effect of opioids on thermoregulatory respons- es and the special antishivering action of meperidine. Ann N Y Acad Sci 1997; 813:792-798.
  22. [109]109. Gouldin WM, Kennedy DT, Small RE. Methadone: History and recommenda- tions for use in analgesia. APS Bulletin 2000; 10:1-11www.ampainsoc.org/pub/ bulletin/sep00/upda1.htm. Accessed 01/29/2011.
  23. [117]117. Kailko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD. Pharmacokinetic-pharmadynamic rela- tionships of controlled-release oxycodo- ne. Clin Pharmacol Ther 1996; 59:52-61.
  24. [130]130. Guay DR. Oral oxymorphone extended- release. Consult Pharm 2010; 25:816-828.
  25. [135]135. Sansone RA, Sansone LA. Tramadol: Sei- zures, serotonin syndrome, and coad- ministered antidepressants. Psychiatry (Edgmont) 2009; 6:17-21.
  26. [136]136. Grond S, Sablotzki A. Clinical pharma- cology of tramadol. Clin Pharmacokinet- ics 2004; 3:879-923.
  27. [139]139. Wade WE, Spruill WJ. Tapentadol hydro- chloride: A centrally acting oral analge- sic. Clin Ther 2009; 31:2804-2818.
  28. [140]140. Barkin RL. Tapentadol: A pharmacother- apeutic focused brief review. Pain Med Network 2009; 24:8,11.
  29. [143]143. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Buris A, Taylor RS. Methadone and buprenor- phine for the management of opioid de- pendence: A systematic review and eco- nomic evaluation. Heath Technol Assess 2007; 11:1-171.
  30. [151]151. Watson PJQ, McQuay HJ, Bullingham RE, Allen MC, Moore RA. Single-dose comparison of buprenorphine 0.3 and 0.6mg i.v. given after operation: Clini- cal effects and plasma concentration. Br J Anaesth 1982; 54:37-43.
  31. [152]152. Walter DS, Inturrisi CE. Absorption, dis- tribution, metabolism, and excretion of buprenorphine in animals and hu- mans. In: Cowan A, Lewis JW (eds). Bu- prenorphine: Combatting Drug Abuse with a Unique Opioid. Wiley-Liss, New York, 1995, pp 113-135.
  32. [157]157. Bullingham RE, McQuay HJ, Dwyer D, Allen MC, Moore RA. Sublingual bu- prenorphine used postoperatively: Clin- ical observations and preliminary phar- macokinetic analysis. Br J Clin Pharmacol 1981; 12:117-122.
  33. [159]159. Reidenberg B, El-Tahtawy A, Munera C, Cipriano A, Tonelli A, Reder R. Absolute bioavailability of a novel buprenorphine transdermal system (BTDS) applied for 7 days. J Clin Pharmacol 2001; 41:1026.
  34. [160]160. Reidenberg B, El-Tahtawy A, Munera C, Cipriano A, Tonelli A, Reder R. Dai- ly pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to 7 days. J Clin Pharmacol 2001; 41:1027.
  35. [163]163. Schmidt WK, Tam SW, Shotzberger GS, Smith Jr DW, Clark R, Vernier VG. Nal- buphine. Drug Alcohol Dep 1985; 14:339- 362.

Cited by

Sorted by citations

Related

Authors
Vallejo, R.
Affiliations
Hospital Quirón Teknon (ES)
Corresponding author
Vallejo, Ricardo
ORCID
Vallejo, Ricardo
Venue
Pain Physician
Publisher
American Society of Interventional Pain Physicians
Published
2011-07-14
Volume
4;14
Issue
4;7
Pages
E343-E360
ISSN
  • 1533-3159 (ISSN-L)
  • 2150-1149
DOI
10.36076/ppj.2011/14/e343
OpenAlex
W89030335
Cited by
124
References
164
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2023: 7 · 2022: 8 · 2021: 8 · 2020: 9 · 2019: 6 · 2018: 9 · 2017: 12 · 2016: 10 · 2015: 6 · 2014: 10 · 2013: 13 · 2012: 18
FWCI
17.88
Type
journal article
Language
en
Open access
Locations
  • Pain Physician (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Surgery › Anesthesia and Pain Management
Keywords
opioids, chronic pain, opioid pharmacology, opium alkaloids, morphine, codeine, thebaine, benzylisoquinoline alkaloids, opium poppy, chronic non-cancer pain, pain management
MeSH terms
Analgesics, Opioid, Chronic Disease, Humans, Pain, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review